EXEL - エクセリクス (Exelixis Inc.)

EXELのニュース

   Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer  2021/11/09 13:00:00 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is now completed for CONTACT-01, the global, phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an immune checkpoint inhibitor and platinum-containing chemotherapy. Patients with advanced non-small cell lung cancer urgently need new treatment opti
   Credit Suisse AG Sells 46,493 Shares of Exelixis, Inc. (NASDAQ:EXEL)  2021/11/08 13:12:41 Dakota Financial News
Credit Suisse AG trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 9.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 426,675 shares of the biotechnology companys stock after selling 46,493 shares during the period. Credit Suisse AGs holdings in Exelixis were worth $7,775,000 []
   Exelixis (NASDAQ:EXEL) Downgraded by TheStreet to C  2021/11/08 06:18:41 Dakota Financial News
TheStreet downgraded shares of Exelixis (NASDAQ:EXEL) from a b- rating to a c rating in a report issued on Thursday morning, TheStreetRatingsTable reports. Other equities research analysts also recently issued research reports about the stock. Royal Bank of Canada decreased their price target on shares of Exelixis from $32.00 to $31.00 and set an outperform []
   TheStreet Lowers Exelixis (NASDAQ:EXEL) to C  2021/11/06 14:54:42 Transcript Daily
Exelixis (NASDAQ:EXEL) was downgraded by analysts at TheStreet from a b- rating to a c rating in a research report issued to clients and investors on Thursday, TheStreetRatingsTable reports. A number of other brokerages have also recently commented on EXEL. Zacks Investment Research raised shares of Exelixis from a hold rating to a strong-buy rating []
   Exelixis (NASDAQ:EXEL) Posts Earnings Results, Misses Estimates By $0.07 EPS  2021/11/06 04:00:41 Transcript Daily
Exelixis (NASDAQ:EXEL) released its quarterly earnings results on Tuesday. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts consensus estimates of $0.19 by ($0.07), MarketWatch Earnings reports. Exelixis had a net margin of 13.10% and a return on equity of 8.45%. During the same quarter in the prior year, the business []
   FDA approves cabozantinib for differentiated thyroid cancer  2021/09/22 13:39:17 US Food and Drug Administration
FDA approved cabozantinib (Cabometyx, Exelixis, Inc.) for patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine.
   Exelixis posts final results from late-stage Cabometyx thyroid cancer trial  2021/09/20 16:00:57 Seeking Alpha
   Exelixis pulls a surprise win in thyroid cancer just days ahead of final Cabometyx readout  2021/09/20 15:30:06 Endpoints News
Exelixis added a thyroid cancer indication to its super-seller Cabometyxs label on Friday months before the FDA was expected to make a decision, and days before the company was set to unveil the final data at #ESMO21. At a median follow-up of 10.1 months, differentiated thyroid cancer patients treated
   Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021  2021/09/20 15:30:00 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX® (cabozantinib) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC). Following a previous announcement that the trial met one of the two primary endpoints of significant improvement versus placebo in progression-free survival (PFS) assessed by blinded independent radiology committee (BIRC; p<0.00
   Exelixis Inc (EXEL) EVP, Scientific Strategy & CSO Peter Lamb Sold $971,850 of Shares  2021/09/18 14:15:05 GuruFocus
Related Stocks: EXEL ,
   The Daily Biotech Pulse: Lilly, Morphic''s Positive Data At ECCO, Humanigen''s COVID Treatment Gets Expedited Review In UK, TransCode IPO  2021/07/09 11:36:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) ( moved on positive analyst action) Ambrx Biopharma Inc. (NYSE: AMAM ) AtriCure, Inc. (NASDAQ: ATRC ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Edwards Lifesciences Corporation (NYSE: EW ) Novo Nordisk A/S (NYSE: NVO ) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) (announced positive Phase 2 data for non-alcoholic steatohepatitis drug) Allogene Therapeutics, Inc.
   Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021  2021/07/08 20:05:00 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Pleas
   Will Exelixis Inventory See Even Decrease Ranges After Unfavourable Information From A Scientific Trial?  2021/07/01 08:21:46 FXNews24
The inventory worth of Exelixis (NASDAQ: EXEL), a genomics-based prescribed drugs firm targeted on oncology remedies, has seen a giant 21% drop during the last 5 buying and selling days, after the corporate introduced a destructive consequence from its medical trials for Cabometyx in beforehand untreated liver most cancers sufferers. Whereas the mixture of Cabometyx and [] The post Will Exelixis Inventory See Even Decrease Ranges After Unfavourable Information From A Scientific Trial? appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .
   Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More  2021/06/30 21:34:20 FXNews24
It was a busy week for the volatile biotech sector with quite a few pipeline and regulatory updates. New drug approvals also continue to be in focus along with news related to vaccines for COVID-19. Recap of the Weeks Most Important Stories: Exelixis Down on Study Update: Shares of Exelixis, Inc. EXEL declined after it [] The post Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .
   Whats Next for Exelixis Stock After Disappointing Advanced Liver Cancer Data  2021/06/30 21:33:07 TipRanks
Decent is not good enough in the biotech world, where a drug needs to meet an exacting standard in order to cut the mustard. Which is the story of the

calendar